Recap: LeMaitre Vascular Q2 Earnings

Shares of LeMaitre Vascular LMAT fell 0.18% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 26.09% year over year to $0.17, which beat the estimate of $0.01.

Revenue of $24,851,000 decreased by 15.71% year over year, which beat the estimate of $17,120,000.

Outlook

Q3 EPS expected between $0.17 and $0.26.

Q3 revenue expected to be between $30,500,000 and $34,500,000.

Conference Call Details

Date: Jul 23, 2020

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/tyncsie7

Price Action

52-week high: $38.64

Company's 52-week low was at $18.76

Price action over last quarter: Up 21.43%

Company Profile

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States. Sales in Germany also contribute a significant proportion of total revenue.